newsfilter
← Latest News
GlobeNewswire·

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability